<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000760.v1.p1" parentStudy="phs000760.v1.p1" createDate="2014-06-16" modDate="2014-09-11">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Scott Boyd, MD, PhD</td><td>Stanford University, Palo Alto, CA, USA</td></tr>
		<tr><td>Funding Source</td><td>U19AI090019</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>P01AI089618</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>U19AI067854</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>1U19AI089987</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Human Responses to Influenza Vaccination</StudyNameEntrez>
	<StudyNameReportPage>Human Responses to Influenza Vaccination</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The data consist of the DNA sequences of antibody gene rearrangements from peripheral blood human B cells of subjects vaccinated with trivalent seasonal influenza or monovalent pandemic H1N1 vaccine. Multiple replicate libraries of immunoglobulin heavy chain gene rearrangements were prepared from each subject for each time point.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>The seven healthy vaccine seroconverter subjects and seven healthy non-seroconverter subjects in the study were recruited at Duke University and were given TIV (Sanofi Pasteur, Swiftwater PA): 2007-2008 Fluzone&#174; vaccine or 2008-2009 Fluzone&#174; vaccine. Blood samples were collected prior to vaccination and on days seven and twenty-one after vaccination. Subject BFI-278 recruited at Stanford University was administered Influenza A (H1N1) 2009 monovalent inactivated vaccination in January 2010. Blood was collected immediately prior to vaccination and on days four to fourteen after vaccination. Ten months after receiving the monovalent H1N1 vaccine, BFI-278 was administered a seasonal trivalent inactivated vaccine that included the Influenza A/California/07/2009-like pandemic H1N1 antigenic component. Blood was drawn from BFI-278 prior to 2010 TIV vaccination, and at days seven and twenty-one post-vaccination.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="24981332"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Influenza Vaccines"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Scott Boyd, MD, PhD</AttName>
			<Institution>Stanford University, Palo Alto, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U19AI090019</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>P01AI089618</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U19AI067854</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>1U19AI089987</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB-IRB" longName="Health/Medical/Biomedical (IRB)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIAID</DacName>
      <DacFullName>NIAID DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000760.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000760.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000760.v1.p1" FileName="Boyd_influenza_DUC_2014-06-15.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical (IRB)</ConsentName>
        <ConsentAbbrev>HMB-IRB</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor must provide documentation of local IRB approval.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
